Redipor Success Drives Cherwell Cleanroom Expansion
Cherwell Laboratories, leading supplier of microbiology media and instruments for pharmaceutical and related industries, is continuing with the investment and expansion programme of its cleanroom production facilities. To increase capacity for future demand from Cherwell’s ever growing customer base, Phase II of the expansion programme will boost Redipor microbiological prepared media plate filling and bottle production capabilities. The new cleanroom facility will be further extended by 230 m2 to more than 950 m2.
Once Phase II is completed in early 2014, Cherwell’s facilities will have doubled in size since July 2012. Phase I delivered new inspection and packing facilities to maintain stringent quality requirements in media preparation prior to Phase II’s increase in Redipor production facilities. Uniquely, to ensure utmost quality Cherwell do not package Redipor products straight from the filling line but first hold them to condition, additionally all products then undergo 100% inspection before final packing.
Demand for Cherwell’s Redipor products continues to rise as new customers experience the benefits of a flexible and reliable supply of these exceptionally high-quality prepared media products. Cherwell’s ability to deliver high volume efficiency with small volume flexibility has helped to increase its market share and develop more export markets, such as Poland. Careful selection of new partners in mainland Europe, has also contributed to securing new customers keen to benefit from a full adaptable service for their industrial microbiological prepared media.
Andy Whittard, Managing Director, Cherwell Laboratories, provided further insight into the reasons for Cherwell’s expanding market. “Despite growing interest in rapid methods, the traditional methods for environmental monitoring are still the most widely used and will continue to be for many years to come. This, coupled with some customers’ movement back to UK and European-based manufacturing, is seeing demand for prepared media continue to increase.”
As Cherwell’s production volumes increase from the current 6.5 million agar plates annually, the company will continue to add to its workforce to maintain its efficiency in supply. Cherwell has already recruited five new staff members since the completion of Phase I, with three additional new starters anticipated before the end of 2013.
“Phase II of our cleanroom extension will provide additional manufacturing space to allow us to invest in further production equipment, such as large scale plate filling systems, media preparators and autoclaves,” added Andy Whittard. “By carefully planning and controlling the works around our own production schedules and with our contractor, Envair Projects, we aim to minimise any impact to customers and product lead times.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance